Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial
Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted...
Gespeichert in:
| Veröffentlicht in: | International Journal of Obesity 2006-07, Vol.30 (7), p.1138-1142 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1142 |
|---|---|
| container_issue | 7 |
| container_start_page | 1138 |
| container_title | International Journal of Obesity |
| container_volume | 30 |
| creator | Gadde, K.M Yonish, G.M Wagner, H.R. II Foust, M.S Allison, D.B |
| description | Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. Design: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. Participants: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2). Interventions: Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. Measurements: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. Results: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) -3.6 (1.0) kg (-3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F(4,96)=11.9; P |
| doi_str_mv | 10.1038/sj.ijo.0803223 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_19494485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188437823</galeid><sourcerecordid>A188437823</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-da2cd723c839a8ed9de176334101150a9f0739562d2325f4a9f83d25c861c1ff3</originalsourceid><addsrcrecordid>eNp1kU2LFDEQhhtR3HH16k1tBL3NbD6703sbFr9gwYPuxUvIJpWZDOlkTNKs_nuzduOgIDkkVD1Vb1XepnmO0QYjKi7yYeMOcYMEooTQB80Ks75bczb0D5sVoqhfI97xs-ZJzgeEEOeIPG7OcMew6DldNd-2JY7xBxQXoLUxtXfgdvvSJjCTLi6G1oU23kKG9i6OEC5b1R4TeDe6oNLPNqlg4ugymFbHUFL0vj5Lcso_bR5Z5TM8W-7z5ub9u69XH9fXnz98utperzWnfVkbRbTpCdWCDkqAGQzgvqOUYYQxR2qwqKcD74ghlHDLakBQQ7gWHdbYWnrevJ37HlP8PkEuss6jwXsVIE5Z4oENjAlewdf_gIc4pVBnkwQPhPKOoQptZminPEgXbCxJ6XoMjK6uCNbV-BYLwWgvCD3J_y7Yg_Jln6Of7j8v_w0unXWKOSew8pjcWD9RYiTvzZT5IKuZcjGzFrxc5p1uRzAnfHGvAm8WQGWtvK1maJdPXF-1GRoqdzFzuabCDtJp8f9Kv5grgipTgj8tT_lXc96qKNUuVdWbLwRhinDV65GgvwAK18lY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219235640</pqid></control><display><type>article</type><title>Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gadde, K.M ; Yonish, G.M ; Wagner, H.R. II ; Foust, M.S ; Allison, D.B</creator><creatorcontrib>Gadde, K.M ; Yonish, G.M ; Wagner, H.R. II ; Foust, M.S ; Allison, D.B</creatorcontrib><description>Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. Design: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. Participants: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2). Interventions: Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. Measurements: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. Results: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) -3.6 (1.0) kg (-3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F(4,96)=11.9; P<0.0001). Three participants in the atomoxetine group and none in the placebo group lost greater than or equal to 5% weight. Side effects were minimal. Conclusion: Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.</description><identifier>ISSN: 0307-0565</identifier><identifier>EISSN: 1476-5497</identifier><identifier>DOI: 10.1038/sj.ijo.0803223</identifier><identifier>PMID: 16418753</identifier><identifier>CODEN: IJOBDP</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adolescent ; Adrenergic Uptake Inhibitors - adverse effects ; Adrenergic Uptake Inhibitors - therapeutic use ; Adult ; Anti-Obesity Agents - adverse effects ; Anti-Obesity Agents - therapeutic use ; atomoxetine ; Atomoxetine Hydrochloride ; Attention deficit hyperactivity disorder ; Biological and medical sciences ; blood glucose ; blood lipids ; Blood pressure ; Body Mass Index ; Body weight ; Clinical trials ; depression ; Diet ; dosage ; Double-Blind Method ; Drug dosages ; drug therapy ; drugs ; Epidemiology ; Feeding. Feeding behavior ; Female ; Fundamental and applied biological sciences. Psychology ; General aspects ; Health Promotion and Disease Prevention ; Heart rate ; Humans ; Internal Medicine ; Lipids ; Medical sciences ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; noradrenergic agents ; Nutrition research ; Obesity ; Obesity - drug therapy ; Obesity - physiopathology ; original-article ; Propylamines - adverse effects ; Propylamines - therapeutic use ; Public Health ; Side effects ; Treatment Outcome ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; waist circumference ; Weight control ; weight loss ; Weight Loss - drug effects ; Women</subject><ispartof>International Journal of Obesity, 2006-07, Vol.30 (7), p.1138-1142</ispartof><rights>Springer Nature Limited 2006</rights><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jul 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-da2cd723c839a8ed9de176334101150a9f0739562d2325f4a9f83d25c861c1ff3</citedby><cites>FETCH-LOGICAL-c537t-da2cd723c839a8ed9de176334101150a9f0739562d2325f4a9f83d25c861c1ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17884409$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16418753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gadde, K.M</creatorcontrib><creatorcontrib>Yonish, G.M</creatorcontrib><creatorcontrib>Wagner, H.R. II</creatorcontrib><creatorcontrib>Foust, M.S</creatorcontrib><creatorcontrib>Allison, D.B</creatorcontrib><title>Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial</title><title>International Journal of Obesity</title><addtitle>Int J Obes</addtitle><addtitle>Int J Obes (Lond)</addtitle><description>Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. Design: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. Participants: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2). Interventions: Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. Measurements: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. Results: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) -3.6 (1.0) kg (-3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F(4,96)=11.9; P<0.0001). Three participants in the atomoxetine group and none in the placebo group lost greater than or equal to 5% weight. Side effects were minimal. Conclusion: Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.</description><subject>Adolescent</subject><subject>Adrenergic Uptake Inhibitors - adverse effects</subject><subject>Adrenergic Uptake Inhibitors - therapeutic use</subject><subject>Adult</subject><subject>Anti-Obesity Agents - adverse effects</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>atomoxetine</subject><subject>Atomoxetine Hydrochloride</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>blood lipids</subject><subject>Blood pressure</subject><subject>Body Mass Index</subject><subject>Body weight</subject><subject>Clinical trials</subject><subject>depression</subject><subject>Diet</subject><subject>dosage</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>drug therapy</subject><subject>drugs</subject><subject>Epidemiology</subject><subject>Feeding. Feeding behavior</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General aspects</subject><subject>Health Promotion and Disease Prevention</subject><subject>Heart rate</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lipids</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>noradrenergic agents</subject><subject>Nutrition research</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Obesity - physiopathology</subject><subject>original-article</subject><subject>Propylamines - adverse effects</subject><subject>Propylamines - therapeutic use</subject><subject>Public Health</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><subject>waist circumference</subject><subject>Weight control</subject><subject>weight loss</subject><subject>Weight Loss - drug effects</subject><subject>Women</subject><issn>0307-0565</issn><issn>1476-5497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU2LFDEQhhtR3HH16k1tBL3NbD6703sbFr9gwYPuxUvIJpWZDOlkTNKs_nuzduOgIDkkVD1Vb1XepnmO0QYjKi7yYeMOcYMEooTQB80Ks75bczb0D5sVoqhfI97xs-ZJzgeEEOeIPG7OcMew6DldNd-2JY7xBxQXoLUxtXfgdvvSJjCTLi6G1oU23kKG9i6OEC5b1R4TeDe6oNLPNqlg4ugymFbHUFL0vj5Lcso_bR5Z5TM8W-7z5ub9u69XH9fXnz98utperzWnfVkbRbTpCdWCDkqAGQzgvqOUYYQxR2qwqKcD74ghlHDLakBQQ7gWHdbYWnrevJ37HlP8PkEuss6jwXsVIE5Z4oENjAlewdf_gIc4pVBnkwQPhPKOoQptZminPEgXbCxJ6XoMjK6uCNbV-BYLwWgvCD3J_y7Yg_Jln6Of7j8v_w0unXWKOSew8pjcWD9RYiTvzZT5IKuZcjGzFrxc5p1uRzAnfHGvAm8WQGWtvK1maJdPXF-1GRoqdzFzuabCDtJp8f9Kv5grgipTgj8tT_lXc96qKNUuVdWbLwRhinDV65GgvwAK18lY</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>Gadde, K.M</creator><creator>Yonish, G.M</creator><creator>Wagner, H.R. II</creator><creator>Foust, M.S</creator><creator>Allison, D.B</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20060701</creationdate><title>Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial</title><author>Gadde, K.M ; Yonish, G.M ; Wagner, H.R. II ; Foust, M.S ; Allison, D.B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-da2cd723c839a8ed9de176334101150a9f0739562d2325f4a9f83d25c861c1ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adrenergic Uptake Inhibitors - adverse effects</topic><topic>Adrenergic Uptake Inhibitors - therapeutic use</topic><topic>Adult</topic><topic>Anti-Obesity Agents - adverse effects</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>atomoxetine</topic><topic>Atomoxetine Hydrochloride</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>blood lipids</topic><topic>Blood pressure</topic><topic>Body Mass Index</topic><topic>Body weight</topic><topic>Clinical trials</topic><topic>depression</topic><topic>Diet</topic><topic>dosage</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>drug therapy</topic><topic>drugs</topic><topic>Epidemiology</topic><topic>Feeding. Feeding behavior</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General aspects</topic><topic>Health Promotion and Disease Prevention</topic><topic>Heart rate</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lipids</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>noradrenergic agents</topic><topic>Nutrition research</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Obesity - physiopathology</topic><topic>original-article</topic><topic>Propylamines - adverse effects</topic><topic>Propylamines - therapeutic use</topic><topic>Public Health</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><topic>waist circumference</topic><topic>Weight control</topic><topic>weight loss</topic><topic>Weight Loss - drug effects</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gadde, K.M</creatorcontrib><creatorcontrib>Yonish, G.M</creatorcontrib><creatorcontrib>Wagner, H.R. II</creatorcontrib><creatorcontrib>Foust, M.S</creatorcontrib><creatorcontrib>Allison, D.B</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>International Journal of Obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gadde, K.M</au><au>Yonish, G.M</au><au>Wagner, H.R. II</au><au>Foust, M.S</au><au>Allison, D.B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial</atitle><jtitle>International Journal of Obesity</jtitle><stitle>Int J Obes</stitle><addtitle>Int J Obes (Lond)</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>30</volume><issue>7</issue><spage>1138</spage><epage>1142</epage><pages>1138-1142</pages><issn>0307-0565</issn><eissn>1476-5497</eissn><coden>IJOBDP</coden><abstract>Background and objective: Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the understanding that noradrenergic agents could be useful in assisting obese individuals to lose weight, we conducted this preliminary study to evaluate short-term efficacy and safety of atomoxetine in obese adults. Design: At 12-week randomised, double-blind, placebo-controlled trial, conducted at Duke University Medical Centre, USA, from May 2004 to December 2004. Participants: A total of 30 obese women (mean (s.e.) body mass index of 36.1 (0.6) kg/m2). Interventions: Participants were randomly assigned to receive atomoxetine (n=15) or placebo (n=15). All participants were advised to follow a balanced hypocaloric diet (500 kcal/day deficit). Atomoxetine therapy was started at 25 mg/day orally, with gradual increase to 100 mg/day over 1 week. Placebo dosing was identical. Measurements: Body weight in kilograms was the primary outcome measure. Other measurements included waist circumference, blood pressure and heart rate, fasting plasma glucose and lipids, and depressive symptoms. Results: Last-observation-carried-forward analysis of the available data for participants who had completed at least one post-randomisation assessment, demonstrated that the atomoxetine group (n=12) lost more body weight over the 12-week period than the placebo (n=14) group (mean (s.e.) -3.6 (1.0) kg (-3.7% loss) vs 0.1 (0.4) kg (0.2% gain); F(4,96)=11.9; P<0.0001). Three participants in the atomoxetine group and none in the placebo group lost greater than or equal to 5% weight. Side effects were minimal. Conclusion: Atomoxetine demonstrated modest short-term weight loss efficacy relative to placebo in this preliminary study of obese women.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16418753</pmid><doi>10.1038/sj.ijo.0803223</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-0565 |
| ispartof | International Journal of Obesity, 2006-07, Vol.30 (7), p.1138-1142 |
| issn | 0307-0565 1476-5497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19494485 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adrenergic Uptake Inhibitors - adverse effects Adrenergic Uptake Inhibitors - therapeutic use Adult Anti-Obesity Agents - adverse effects Anti-Obesity Agents - therapeutic use atomoxetine Atomoxetine Hydrochloride Attention deficit hyperactivity disorder Biological and medical sciences blood glucose blood lipids Blood pressure Body Mass Index Body weight Clinical trials depression Diet dosage Double-Blind Method Drug dosages drug therapy drugs Epidemiology Feeding. Feeding behavior Female Fundamental and applied biological sciences. Psychology General aspects Health Promotion and Disease Prevention Heart rate Humans Internal Medicine Lipids Medical sciences Medicine Medicine & Public Health Metabolic Diseases Middle Aged noradrenergic agents Nutrition research Obesity Obesity - drug therapy Obesity - physiopathology original-article Propylamines - adverse effects Propylamines - therapeutic use Public Health Side effects Treatment Outcome Vertebrates: anatomy and physiology, studies on body, several organs or systems waist circumference Weight control weight loss Weight Loss - drug effects Women |
| title | Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A03%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atomoxetine%20for%20weight%20reduction%20in%20obese%20women:%20a%20preliminary%20randomised%20controlled%20trial&rft.jtitle=International%20Journal%20of%20Obesity&rft.au=Gadde,%20K.M&rft.date=2006-07-01&rft.volume=30&rft.issue=7&rft.spage=1138&rft.epage=1142&rft.pages=1138-1142&rft.issn=0307-0565&rft.eissn=1476-5497&rft.coden=IJOBDP&rft_id=info:doi/10.1038/sj.ijo.0803223&rft_dat=%3Cgale_proqu%3EA188437823%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219235640&rft_id=info:pmid/16418753&rft_galeid=A188437823&rfr_iscdi=true |